Directory

◇Not a peptide·Small molecule

A small-molecule compound that researchers and self-experimenters study for its effects on metabolism, body composition, cellular energy, and healthy aging. Often discussed as a tool for understanding and potentially optimizing metabolic flexibility through NNMT inhibition.

◇Not a peptide·Fusion protein

An investigational soluble activin receptor type IIB fusion protein studied for blocking myostatin-family ligands and increasing muscle mass in wasting disorders.

A Semax-derived cognitive research peptide marketed in nootropic communities, with claims centered on neurotrophic signaling, focus, mood, and stress resilience.

An experimental peptidomimetic studied preclinically for targeting adipose vasculature through prohibitin-related mechanisms, with major translational and safety uncertainty.

◇Not a peptide·Nucleotide analog

A nucleotide analog and AMPK-pathway research tool studied in cellular energy sensing, exercise-mimetic biology, cardiometabolic research, and anti-doping contexts.

A synthetic fragment of growth hormone designed to isolate GH's fat-mobilizing effects without its growth-promoting or blood-sugar-altering activity — a tool researchers and self-experimenters study for body composition and joint health.

An erythropoietin-derived peptide studied for tissue-protective and anti-inflammatory signaling without the red-blood-cell stimulation associated with EPO.

◇Not a peptide·Vitamin

An essential water-soluble vitamin required for red blood cell formation, nervous-system function, DNA synthesis, and one-carbon metabolism; it is not a peptide.

◇Not a peptide·Protein toxin

A bacterial neurotoxin protein used clinically in tightly controlled doses for neuromuscular, migraine, autonomic, and cosmetic indications; it is not a peptide supplement.

A stable 15-amino-acid peptide fragment derived from a protein in human gastric juice, widely studied in preclinical models for tissue protection and repair across gut, tendon, muscle, and vascular tissue.

An investigational long-acting amylin analog studied for appetite regulation, satiety, obesity, and combination use with semaglutide in CagriSema.

A fixed-dose investigational metabolic combination pairing the long-acting amylin analog cagrilintide with the GLP-1 receptor agonist semaglutide, studied for obesity and type 2 diabetes.

A short bioregulator peptide discussed in cardiovascular-aging research traditions, usually represented by the tetrapeptide Ala-Glu-Asp-Arg.

A bioregulator peptide product discussed in cartilage, joint, and connective-tissue aging contexts, with evidence best treated as preliminary and formulation-dependent.

A parenteral preparation of small peptides and amino acids derived from porcine brain protein, used clinically for decades across stroke, dementia, and traumatic brain injury recovery in many countries outside the US.

A synthetic analog of growth-hormone-releasing hormone (GHRH) engineered for extended half-life, studied for prolonged stimulation of pulsatile GH and IGF-1 release — a tool researchers and self-experimenters use to explore their own endocrine biology.

A compounded blend pairing a short-acting GHRH analog (CJC-1295 without DAC) with the selective GHS peptide Ipamorelin — popular in self-experimentation for its goal of mimicking physiologic, pulsatile growth hormone release rather than sustained elevation.

A bioregulator peptide product discussed in immune and aging research contexts, with claims centered on immune resilience and cellular regulation rather than a single validated indication.

A potent opioid heptapeptide originally isolated from frog skin secretions and studied as a tool compound for mu-opioid receptor pharmacology and analgesia research.

A nine-amino-acid neuropeptide first isolated in 1977 from the cerebral venous blood of slow-wave-sleeping rabbits — a decades-long scientific puzzle studied for effects on sleep, stress tolerance, and neuroendocrine signaling.

A synthetic tetrapeptide derived from the pineal preparation Epitalamin, studied for decades in Russian research for effects on telomerase activity, melatonin rhythm, and age-related biomarkers.

◇Not a peptide·Glycoprotein hormone

A glycoprotein hormone that stimulates red blood cell production, used clinically for specific anemia indications and tightly controlled because of thrombotic and doping risks.

A cell-penetrating D-retro-inverso peptide studied preclinically for disrupting FOXO4-p53 interactions in senescent-cell research models.

◇Not a peptide·Protein cytokine

A TGF-beta family protein better known as myostatin, the major negative regulator of skeletal muscle growth and a target in muscle-wasting research.

A naturally occurring copper-binding tripeptide studied for skin regeneration, hair biology, and extracellular matrix remodeling, with one of the most mature cosmetic and wound-healing research literatures in the peptide space.

A growth hormone secretagogue peptide that activates ghrelin/GHS receptors and is studied for GH release, appetite signaling, and endocrine-axis pharmacology.

A compounded peptide blend typically combining GHK-Cu, larazotide acetate, and additional peptides — formulated around the intersection of skin quality, hair support, and gut-barrier integrity, and studied by self-experimenters interested in that multi-tissue angle.

A compounded recovery and skin-focused peptide blend combining BPC-157, GHK-Cu, and TB-500; its rationale comes from component-level tissue-repair, copper-peptide, and cell-migration research.

An endogenous tripeptide and the body's most abundant intracellular antioxidant, used clinically as an IV adjunct in hepatic, dermatologic, and neurological contexts and studied for oxidative stress and detoxification biology.

A synthetic form of gonadotropin-releasing hormone studied and used to probe or stimulate pituitary LH and FSH release in reproductive endocrinology.

◇Not a peptide·Glycoprotein hormone

A glycoprotein hormone used clinically in fertility and endocrine contexts and discussed in peptide-adjacent markets because it acts on LH/CG receptor signaling.

A synthetic growth hormone secretagogue peptide studied for potent ghrelin-receptor-mediated GH release, with broader endocrine and cardiovascular research interest.

◇Not a peptide·Protein hormone

Recombinant human growth hormone used clinically for defined growth-hormone deficiency and wasting indications, with major monitoring, abuse, and endocrine-risk considerations.

◇Not a peptide·Gonadotropin hormone preparation

A gonadotropin preparation containing FSH and LH activity, used clinically in fertility medicine and discussed in peptide-adjacent endocrine markets.

A mitochondrial-derived peptide studied for cellular stress resistance, apoptosis modulation, metabolic aging, neuroprotection, and mitochondrial communication.

A modified analog of insulin-like growth factor 1 engineered with a dramatically longer active window, widely used as a research reagent for studying anabolic signaling, muscle biology, and the downstream effects of the GH/IGF-1 axis.

A synthetic pentapeptide that gently nudges the pituitary to release its own growth hormone — studied for clean, selective GH pulses without the cortisol or prolactin effects of earlier secretagogues.

A short kisspeptin fragment studied for hypothalamic GnRH stimulation, reproductive hormone signaling, puberty biology, and fertility research.

A compounded peptide blend that combines KPV, GHK-Cu, BPC-157, and TB-500 — studied individually for tissue repair, inflammation modulation, and skin quality, and packaged together in compounding-pharmacy contexts.

A short tripeptide derived from α-melanocyte-stimulating hormone, studied for anti-inflammatory effects in gut, skin, and ocular tissue — without the pigmentation activity of its parent hormone.

◇Not a peptide·Amino acid derivative

An amino acid derivative involved in fatty-acid transport into mitochondria, used medically for carnitine deficiency and studied for metabolism, exercise, and body composition.

◇Not a peptide·Cosmetic blend

A non-peptide cosmetic injection product marketed for localized fat reduction or skin aesthetics, with formulation and regulatory status varying by market.

◇Not a peptide·Nutrient blend

A non-peptide lipotropic nutrient blend typically built around methionine, inositol, choline, and sometimes L-carnitine, with formulation-dependent claims.

◇Not a peptide·Nutrient blend

A non-peptide lipotropic injection blend typically built around methionine, inositol, choline, L-carnitine, and vitamin B12; formulations vary and weight-loss claims are much less established than the nutrition biology.

A once-daily GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with a long clinical evidence base preceding semaglutide.

The only human cathelicidin antimicrobial peptide — a 37-amino-acid fragment of hCAP-18 studied for its broad antimicrobial activity, wound-healing signaling, and immunomodulatory effects across preclinical and early clinical work.

A synthetic alpha-MSH analog best known through afamelanotide, a melanocortin-1 receptor agonist approved for erythropoietic protoporphyria under regulated use.

A synthetic pan-melanocortin agonist originally developed at the University of Arizona as a sunless-tanning research candidate and later studied for central effects on sexual arousal and appetite regulation.

A mechano growth factor-related peptide concept tied to IGF-1 splice-variant biology, muscle loading, tissue repair, and satellite-cell research.

A 16-amino-acid peptide encoded inside mitochondrial DNA itself, studied for effects on insulin sensitivity, exercise adaptation, and age-related metabolic decline — a fascinating window into mitochondrial-nuclear signaling.

◇Not a peptide·Coenzyme

A central coenzyme in cellular energy, DNA repair, and sirtuin biology, studied extensively in aging and metabolic health — most commonly researched via oral precursors like nicotinamide riboside (NR) and NMN.

An endogenous hypothalamic neuropeptide studied for arousal, wakefulness, appetite, reward signaling, and sleep-wake regulation through orexin receptors.

A cyclic nonapeptide hormone used clinically in obstetrics and studied for social bonding, lactation, reproductive physiology, and neuroendocrine signaling.

A short peptide analog discussed in neuropsychiatric research for TREK-1 potassium-channel biology, antidepressant-like mechanisms, and neuroplasticity models.

A PEGylated version of mechano growth factor concepts, discussed in muscle-repair and IGF-1 splice-variant research with limited clinical validation.

A short synthetic tripeptide from the bioregulator peptide tradition, studied mainly in neuroprotection, brain aging, and stress-response research models.

A synthetic p53-derived research peptide studied preclinically for cancer-cell membrane effects and HDM-2-related mechanisms, not an approved cancer therapy.

An FDA-approved synthetic cyclic heptapeptide (Vyleesi) that acts on central melanocortin receptors to treat hypoactive sexual desire disorder in premenopausal women — the first approved centrally-acting treatment for this indication.

An investigational Eli Lilly triple agonist at the GLP-1, GIP, and glucagon receptors, currently in Phase 3 development with some of the largest weight-loss effect sizes reported in clinical pharmacotherapy.

A nonstandard metabolic stack pairing retatrutide, a GLP-1/GIP/glucagon triple agonist, with tirzepatide, a GLP-1/GIP dual agonist; the blend is vendor-driven rather than clinically validated as a unit.

A synthetic heptapeptide analog of the natural immunomodulator tuftsin, studied for its anxiolytic, immunomodulatory, and neurotrophic effects — and registered as an anti-anxiety pharmaceutical in Russia.

A long-acting GLP-1 receptor agonist originally developed for type 2 diabetes and now FDA-approved for chronic weight management, with an active research pipeline in cardiometabolic, liver, and neurological disease.

A synthetic heptapeptide derived from an ACTH fragment, studied for neurotrophic, cognitive, and neuroprotective effects — and registered as an intranasal pharmaceutical in Russia for stroke and cognitive indications.

A synthetic analog of the active N-terminal region of human growth-hormone-releasing hormone, historically FDA-approved for pediatric GH deficiency and studied as a more physiologic approach to restoring pulsatile GH secretion.

◇Not a peptide·Small molecule

A small-molecule estrogen-related receptor agonist studied preclinically for exercise-mimetic effects, mitochondrial metabolism, endurance signaling, and energy expenditure.

A cosmetic neuropeptide ingredient related to Argireline concepts, marketed for expression-line reduction through topical modulation of facial muscle signaling.

A synthetic mitochondria-targeting tetrapeptide that concentrates in the inner mitochondrial membrane and stabilizes cardiolipin, studied in Phase 2–3 programs for primary mitochondrial disease, Barth syndrome, and dry age-related macular degeneration.

An investigational GLP-1/glucagon receptor dual agonist in clinical development for obesity and metabolic dysfunction-associated steatohepatitis.

A nonstandard metabolic stack pairing survodutide, an investigational GLP-1/glucagon dual agonist, with tirzepatide, a GIP/GLP-1 dual agonist; the combination itself has no established clinical evidence base.

A short synthetic peptide corresponding to an active region of thymosin β4, studied in preclinical models of wound healing, cardiac repair, and tissue regeneration — often compared with, but distinct from, full-length Tβ4.

A vendor shorthand that usually refers to a thymosin beta-4 fragment; interpretation depends on whether the product is TB-500, full thymosin beta-4, or another fragment.

A stabilized synthetic analog of GHRH, FDA-approved for reducing abdominal fat in HIV-associated lipodystrophy and actively studied for visceral adiposity, liver disease, and cognitive endpoints in related contexts.

A growth-hormone-axis blend pairing tesamorelin, a GHRH analog with an FDA-approved HIV-lipodystrophy indication, with ipamorelin, a selective growth hormone secretagogue.

A thymus-derived peptide preparation from Russian bioregulator traditions, studied and marketed for immune-aging, thymic signaling, and immunomodulatory research contexts.

A 28-amino-acid immunomodulatory peptide naturally produced by the thymus, registered as a pharmaceutical in over 30 countries (as Zadaxin/Thymalfasin) for hepatitis B, hepatitis C, and immune-adjunct use — not FDA-approved in the United States.

A dual GIP/GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, producing the largest Phase 3 weight-loss effects reported to date in an FDA-approved pharmacotherapy.

A short bioregulator peptide discussed in vascular aging and endothelial-function research traditions, usually represented by the tripeptide Lys-Glu-Asp.

An endogenous neuroimmune peptide studied for smooth-muscle relaxation, vasodilation, epithelial barrier signaling, pulmonary biology, and inflammatory regulation.

A compounded blend combining BPC-157 and TB-500 — two research peptides with preclinical tissue-repair literature — marketed as a "recovery stack" rather than a standardized pharmaceutical, with the research picture derived almost entirely from component-level studies.